Cryptotanshinone
(Synonyms: 隐丹参酮; Cryptotanshinon; Tanshinone c) 目录号 : GN10501
Cryptotanshinone是从丹参(Salvia miltiorrhiza Bunge)的根中提取的天然化合物,具有抗肿瘤活性,能够抑制信号转导及转录激活蛋白3(STAT3),IC50值为4.6μM。
Cas No.:35825-57-1
Sample solution is provided at 25 µL, 10mM.
Cryptotanshinone is a natural compound extracted from the roots of Salvia miltiorrhiza Bunge, exhibiting antitumor activity by inhibiting Signal Transducer and Activator of Transcription 3 (STAT3) with an IC50 value of 4.6μM[1, 2]. Cryptotanshinone possesses multiple biological activities, including antitumor, anti-inflammatory, anti-fibrotic, and anti-angiogenic effects[3, 4].
In vitro, Cryptotanshinone (20μM) treatment of A549 cells for 24h reduced the percentage of cells in the G0/G1 phase, increased the percentage of cells in the G2/M phase, induced G2/M phase arrest, and promoted apoptosis along with the expression of apoptotic genes[5]. In another study, pretreatment of H9C2 cells with Cryptotanshinone (3μM) for 1h significantly prevented chronic hypoxia-induced cell injury, restored cellular ATP levels, reduced mitochondrial superoxide levels, and decreased intracellular NO and calcium levels[6].
In vivo, Cryptotanshinone (50mg/kg/day) administered via gastric gavage for 4 weeks in a mouse model of cardiac remodeling induced by aortic banding (AB) surgery improved pressure overload-induced cardiac dysfunction, attenuated cardiac hypertrophy, and reduced cardiac fibrosis[7]. Additionally, Cryptotanshinone (40mg/kg/day) administered orally in a CCl4-induced liver fibrosis mouse model ameliorated liver fibrosis, inhibited the activation of hepatic stellate cells, and suppressed collagen production[8].
References:
[1] Zheng J, Zhou Y, Zhang P, et al. Salvia miltiorrhiza Bunge: Bioactive Compounds and Bioactivities[J]. Int. J. Trad. Nat. Med, 2015, 5(1): 52-81.
[2] Hua Y, Yuan X, Shen Y, et al. Novel STAT3 inhibitors targeting STAT3 dimerization by binding to the STAT3 SH2 domain[J]. Frontiers in Pharmacology, 2022, 13: 836724.
[3] Li H, Gao C, Liu C, et al. A review of the biological activity and pharmacology of cryptotanshinone, an important active constituent in Danshen[J]. Biomedicine & Pharmacotherapy, 2021, 137: 111332.
[4] Hur J M, Shim J S, Jung H J, et al. Cryptotanshinone but not tanshinone IIA inhibits angiogenesis in vitro[J]. Experimental & molecular medicine, 2005, 37(2): 133-137.
[5] Chen L, Wang H J, Xie W, et al. Cryptotanshinone inhibits lung tumorigenesis and induces apoptosis in cancer cells in vitro and in vivo[J]. Molecular medicine reports, 2014, 9(6): 2447-2452.
[6] Jin H J, Li C G. Tanshinone IIA and cryptotanshinone prevent mitochondrial dysfunction in hypoxia‐induced H9c2 cells: association to mitochondrial ROS, intracellular nitric oxide, and calcium levels[J]. Evidence‐Based Complementary and Alternative Medicine, 2013, 2013(1): 610694.
[7] Li W, Yan H, Zhou Z, et al. Cryptotanshinone attenuated pathological cardiac remodeling in vivo and in vitro experiments[J]. Oxidative Medicine and Cellular Longevity, 2023, 2023(1): 4015199.
[8] Li Z, Zheng Y, Zhang L, et al. Cryptotanshinone alleviates liver fibrosis via inhibiting STAT3/CPT1A-dependent fatty acid oxidation in hepatic stellate cells[J]. Chemico-Biological Interactions, 2024, 399: 111119.
Cryptotanshinone是从丹参(Salvia miltiorrhiza Bunge)的根中提取的天然化合物,具有抗肿瘤活性,能够抑制信号转导及转录激活蛋白3(STAT3),IC50值为4.6μM[1, 2]。Cryptotanshinone具有抗肿瘤、抗炎、抗纤维化、抗血管生成等活性[3, 4]。
在体外,Cryptotanshinone(20μM)处理A549细胞24h,降低了G0/G1期细胞的百分比,增加了G2/M期的百分比,导致了细胞G2/M期停滞,诱导了细胞凋亡和凋亡基因的表达[5]。Cryptotanshinone(3μM)预处理H9C2细胞1h,显著预防了慢性缺氧诱导的细胞损伤,恢复了细胞ATP含量,降低了线粒体内超氧化物水平,降低了细胞内NO和钙水平[6]。
在体内,Cryptotanshinone(50mg/kg/day)通过胃灌注治疗主动脉束缚(AB)手术构建的心脏重塑模型小鼠4周,改善了小鼠压力超负荷引起的心脏功能障碍,减弱了心脏肥大并减少心脏纤维化[7]。Cryptotanshinone(40mg/kg/day)通过口服治疗CCl4诱导的肝纤维化小鼠,改善了小鼠的肝纤维化,抑制了小鼠肝星状细胞的激活,抑制了胶原蛋白的产生[8]。
Cell experiment [1]: | |
Cell lines | A549 cells |
Preparation Method | A549 cells were seeded in a 6-well plate at a density of 1x105/ml and treated at a final Cryptotanshinone concen tration of 20µM for 24h. Cells were trypsinized, centrifuged (4˚C, 800g/min, 10min), washed with PBS and fixed with cold 70% ethanol/30% PBS at 4˚C overnight. Cells were digested by RNase A, and then stained with 1% propidium iodide at 37˚C for 30min. The DNA profiles were determined within 4h of staining by flow cytometry. The expresions of cell cycle and apoptosis-associated genes was tested using Cell Cycle PCR Array. |
Reaction Conditions | 20μM; 24h |
Applications | Following treatment with 20µM Cryptotanshinone, the percentage of A549 cells in G0/G1 phase was decreased while that in G2/M phases was increased. Cryptotanshinone was able to cause G2/M phase arrest in A549 cells. |
Animal experiment [2]: | |
Animal models | Male C57BL/6J mice |
Preparation Method | After Aortic Banding (AB) surgery, the mice were divided into four groups randomly: saline group (VEH), Cryptotanshinone (CTS) group, AB group, and AB+CTS group (n=10 in the sham group, n=10 in the AB group). Three days after AB surgery, mice were administrated with Cryptotanshinone for 4 weeks (50mg/kg, gastric perfusion). At the end of the treatment, the surviving mice were used for accessing cardiac function. And mice were euthanized with an overdose of sodium pentobarbital (200mg/kg, intraperitoneal injection). Hearts were collected for other experiments. |
Dosage form | 50mg/kg; 4 weeks; gastric perfusion |
Applications | Cryptotanshinone treatment improved pressure overload-induced cardiac dysfunction, attenuated cardiac hypertrophy, and reduced cardiac fibrosis in mice. |
References: |
Cas No. | 35825-57-1 | SDF | |
别名 | 隐丹参酮; Cryptotanshinon; Tanshinone c | ||
化学名 | (1R)-1,6,6-trimethyl-2,7,8,9-tetrahydro-1H-naphtho[1,2-g][1]benzofuran-10,11-dione | ||
Canonical SMILES | CC1COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)C | ||
分子式 | C19H20O3 | 分子量 | 296.35 |
溶解度 | ≥ 4.23mg/mL in DMSO | 储存条件 | -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 3.3744 mL | 16.8719 mL | 33.7439 mL |
5 mM | 0.6749 mL | 3.3744 mL | 6.7488 mL |
10 mM | 0.3374 mL | 1.6872 mL | 3.3744 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet